Amneal Pharmaceuticals Non-GAAP EPS of $0.19 in-line, revenue of $559M beats by $24.56M, revises FY earning guidance

Aug. 05, 2022 6:04 AM ETAmneal Pharmaceuticals, Inc. (AMRX)By: Deepa Sarvaiya, SA News Editor
  • Amneal Pharmaceuticals press release (NYSE:AMRX): Q2 Non-GAAP EPS of $0.19 in-line.
  • Revenue of $559M (+4.5% Y/Y) beats by $24.56M.
  • FY22 Guidance: Reaffirms Net revenue to $2.15B-$2.25B vs consensus of $2.17B; Adj EPS from prior $0.80-$0.85 to $0.65-$0.70 vs consensus of $0.80; Adj. EBITDA from prior of $540M-$560M to $500M-$520M 

Recommended For You

Comments

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.